Adjuvant Pelvic Radiation Therapy ± Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 4, 2016, Pages 335-339

  Nagar, Himanshu ^a   Yan, Weisi ^a   Parashar, Bhupesh ^a   Nori, Dattatreyudu ^a   Chao, K S C ^a   Christos, Paul ^a   Gupta, Divya ^a   Holcomb, Kevin ^a   Caputo, Thomas ^a   Wernicke, A Gabriella ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

brachytherapy; EBRT; high grade endometrial cancer

Indexed keywords

ABDOMINAL HYSTERECTOMY; ADJUVANT RADIOTHERAPY; ADULT; AGED; ARTICLE; BLACK PERSON; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CAUCASIAN; CAUSE SPECIFIC SURVIVAL; CLEAR CELL CARCINOMA; COHORT ANALYSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RACE DIFFERENCE; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; VERY ELDERLY; ADENOCARCINOMA, CLEAR CELL; CANCER REGISTRY; CANCER STAGING; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE;

ADENOCARCINOMA, CLEAR CELL; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SEER PROGRAM; SURVIVAL RATE;

EID: 84961884194     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000065     Document Type: Article

References (19)

1. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54:278-291.
2. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419-427.
3. Creutzberg C, Van Putten W, Koper P, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma: Multicentre randomized trial: PORTEC Study Group: post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355:1404-1411.
4. Keys H, Roberts J, Brunetto V, et al. A phase III trial of surgery with or without adjuvant external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncologic Group study. Gynecol Oncol. 2004;92:744-751.
5. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, noninferiority, randomised trial. Lancet. 2010;375:816-823.
6. Boruta DM, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: a society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-153.
7. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104.
8. Eifel PJ. The role of adjuvant radiation therapy for stage I endometrial cancer: does meta-analysis reveal the answer? J Natl Cancer Inst. 2012;104:1615-1616.
9. Lindemann K, Onsrud M, Kristensen G, et al. Survival after radiation therapy for early-stage endometrial carcinoma: the Oslo study revisited after up to 43 years of follow-up. J Clin Oncol. 2012;30(suppl):abstr 5008.
10. Kim A, Schreiber D, Rineer J, et al. Impact of adjuvant externalbeam radiation therapy in early-stage uterine papillary serous and clear cell carcinoma. Int J Radiat Oncol Biol Phys. 2011;81: e639-e644.
11. Sorbe BG, Horvath G, Andersson H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study-quality-of-life analysis. Int J Gynecol Cancer. 2012;22:1281-1288.
12. Reisinger S, Nori D, Lewis JL. Postoperative intravaginal radiation therapy as an adjunct to external irradiation in high risk endometrial adenocarcinoma: An evaluation of two different dose schedules. Endocuriether/Hyperthermia Oncol. 1991;7:35-41.
13. Grice J, Marit E, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69:69-73.
14. Chan J, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 2003;90:181-185.
15. Bristow R, Asrari F, Trimble E, et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcomes of locoregional disease (stage I-III) disease. Gynecol Oncol. 2001;81: 279-286.
16. Thomas M, Mariani A, Cliby W, et al. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;107:186-189.
17. Slomovitz B, Burke T, Eifel P, et al. Uterine papillary serous carcinoma: a single institution review of 129 cases. Gynecol Oncol. 2003;91:463-469.
18. Hamilton C, Liou W, Osann K, et al. Impact of adjuvant therapy on survival with early stage papillary serous carcinoma. Int J Radiol Oncol Biol Phys. 2005;63:839-844.
19. Jagsi R, Abrahamse P, Hawley ST, et al. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer. 2012;118:333-341.